333 related articles for article (PubMed ID: 31959756)
21. A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer.
Franco YL; Ramakrishnan V; Vaidya TR; Mody H; Perez L; Ait-Oudhia S
J Pharmacokinet Pharmacodyn; 2021 Apr; 48(2):273-293. PubMed ID: 33389550
[TBL] [Abstract][Full Text] [Related]
22. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
[TBL] [Abstract][Full Text] [Related]
23. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
Nuciforo P; Pascual T; Cortés J; Llombart-Cussac A; Fasani R; Paré L; Oliveira M; Galvan P; Martínez N; Bermejo B; Vidal M; Pernas S; López R; Muñoz M; Garau I; Manso L; Alarcón J; Martínez E; Rodrik-Outmezguine V; Brase JC; Villagrasa P; Prat A; Holgado E
Ann Oncol; 2018 Jan; 29(1):170-177. PubMed ID: 29045543
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.
Hou Y; Nitta H; Wei L; Banks PM; Parwani AV; Li Z
Clin Breast Cancer; 2018 Apr; 18(2):e237-e244. PubMed ID: 29198959
[TBL] [Abstract][Full Text] [Related]
25. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
Hanker AB; Garrett JT; Estrada MV; Moore PD; Ericsson PG; Koch JP; Langley E; Singh S; Kim PS; Frampton GM; Sanford E; Owens P; Becker J; Groseclose MR; Castellino S; Joensuu H; Huober J; Brase JC; Majjaj S; Brohée S; Venet D; Brown D; Baselga J; Piccart M; Sotiriou C; Arteaga CL
Clin Cancer Res; 2017 Aug; 23(15):4323-4334. PubMed ID: 28381415
[No Abstract] [Full Text] [Related]
26. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
[TBL] [Abstract][Full Text] [Related]
27. Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer.
Castagnoli L; Iorio E; Dugo M; Koschorke A; Faraci S; Canese R; Casalini P; Nanni P; Vernieri C; Di Nicola M; Morelli D; Tagliabue E; Pupa SM
J Cell Physiol; 2019 Feb; 234(2):1768-1779. PubMed ID: 30132876
[TBL] [Abstract][Full Text] [Related]
28. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.
Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
J Clin Oncol; 2018 Mar; 36(8):741-748. PubMed ID: 29244528
[TBL] [Abstract][Full Text] [Related]
29. Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination.
Swain SM; Tang G; Lucas PC; Robidoux A; Goerlitz D; Harris BT; Bandos H; Geyer CE; Rastogi P; Mamounas EP; Wolmark N
Breast Cancer Res Treat; 2019 Nov; 178(2):389-399. PubMed ID: 31428908
[TBL] [Abstract][Full Text] [Related]
30. Effects of trastuzumab and lapatinib on HER2 positive breast cancer treatment.
Jia W; Wang TZ
J Biol Regul Homeost Agents; 2019 Mar-Apr,; 33(2):551-555. PubMed ID: 30907562
[TBL] [Abstract][Full Text] [Related]
31. Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer.
Zazo S; González-Alonso P; Martín-Aparicio E; Chamizo C; Luque M; Sanz-Álvarez M; Mínguez P; Gómez-López G; Cristóbal I; Caramés C; García-Foncillas J; Eroles P; Lluch A; Arpí O; Rovira A; Albanell J; Madoz-Gúrpide J; Rojo F
Mol Cancer Ther; 2020 Aug; 19(8):1696-1707. PubMed ID: 32404410
[TBL] [Abstract][Full Text] [Related]
32. Deciphering trastuzumab resistance in residual tumor according to HER2 status after neoadjuvant trastuzumab containing regimen in HER2 positive breast cancer patients might help to choose further adjuvant anti-HER2 treatment.
Abduyev Z; Altundag K
J BUON; 2019; 24(5):2208. PubMed ID: 31786900
[No Abstract] [Full Text] [Related]
33. Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer.
Horii R; Nitta H; Nojima M; Maruyama R; Ueno T; Ito Y; Ohno S; Banks P; Kanda H; Akiyama F
Virchows Arch; 2021 Jul; 479(1):13-21. PubMed ID: 33496805
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
Xu ZQ; Zhang Y; Li N; Liu PJ; Gao L; Gao X; Tie XJ
BMJ Open; 2017 Mar; 7(3):e013053. PubMed ID: 28289045
[TBL] [Abstract][Full Text] [Related]
35. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
36. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
[TBL] [Abstract][Full Text] [Related]
37. When to Add Additional Anti-HER2 Therapy to Adjuvant Trastuzumab.
Zimmer AS; Denduluri N
Curr Oncol Rep; 2019 Nov; 21(12):109. PubMed ID: 31781874
[TBL] [Abstract][Full Text] [Related]
38. HER2-positive breast cancer: Current and new therapeutic strategies.
Escrivá-de-Romaní S; Arumí M; Bellet M; Saura C
Breast; 2018 Jun; 39():80-88. PubMed ID: 29631097
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.
Chaganty BKR; Qiu S; Gest A; Lu Y; Ivan C; Calin GA; Weiner LM; Fan Z
Cancer Lett; 2018 Aug; 430():47-56. PubMed ID: 29746929
[TBL] [Abstract][Full Text] [Related]
40. Evaluating Trastuzumab in the treatment of HER2 positive breast cancer.
Jaques R; Xu S; Matsakas A
Histol Histopathol; 2020 Oct; 35(10):1059-1075. PubMed ID: 32323293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]